Tags

Type your tag names separated by a space and hit enter

Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
Int Clin Psychopharmacol 2004; 19(6):331-6IC

Abstract

The primary endpoints in this study were the remission rates [final Hamilton Rating Scale for Anxiety (HAM-A) total score < or =7] and reduction from baseline in the HAM-A total score in patients with generalized anxiety disorder (GAD) and no associated depression. Patients with GAD (DSM-IV and HAM-A total score >18) were randomly assigned to treatment with venlafaxine XR or placebo for 8 weeks. A 1-week placebo run-in period preceded the double-blind phase. Patients with a >20% drop in their total HAM-A score during the run-in period, were excluded from the double-blind phase. All patients started therapy with 75 mg/day venlafaxine XR or matched placebo. Patients with less than 30% decrease in their HAM-A total score at the end of the second week, doubled their dose. Patients on the 150 mg/day dose underwent a 1-week taper period. Of the 24 patients in the venlafaxine XR group, 62.5% achieved remission versus 9.1% in the placebo group (P=0.0006). The mean decrease from baseline in HAM-A total score was 19.2 points for the venlafaxine XR group and 10.8 points for the placebo group (P<0.001). Eleven placebo-treated patients and seven venlafaxine XR treated patients doubled their dose at the end of the second week of double-blind treatment. No patient interrupted therapy because of side-effects. No changes in systolic or diastolic blood pressure were observed. Venlafaxine XR 75-150 mg/day was well tolerated. The remission rates achieved with venlafaxine 75-150 mg/day in non-depressed GAD patients were high with good tolerability.

Authors+Show Affiliations

Third Department of Psychiatry, AHEPA Hospital, Medical School, University of Thessaloniki, Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15486518

Citation

Nimatoudis, I, et al. "Remission Rates With Venlafaxine Extended Release in Greek Outpatients With Generalized Anxiety Disorder. a Double-blind, Randomized, Placebo Controlled Study." International Clinical Psychopharmacology, vol. 19, no. 6, 2004, pp. 331-6.
Nimatoudis I, Zissis NP, Kogeorgos J, et al. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol. 2004;19(6):331-6.
Nimatoudis, I., Zissis, N. P., Kogeorgos, J., Theodoropoulou, S., Vidalis, A., & Kaprinis, G. (2004). Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. International Clinical Psychopharmacology, 19(6), pp. 331-6.
Nimatoudis I, et al. Remission Rates With Venlafaxine Extended Release in Greek Outpatients With Generalized Anxiety Disorder. a Double-blind, Randomized, Placebo Controlled Study. Int Clin Psychopharmacol. 2004;19(6):331-6. PubMed PMID: 15486518.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. AU - Nimatoudis,I, AU - Zissis,N P, AU - Kogeorgos,J, AU - Theodoropoulou,S, AU - Vidalis,A, AU - Kaprinis,G, PY - 2004/10/16/pubmed PY - 2005/2/16/medline PY - 2004/10/16/entrez SP - 331 EP - 6 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 19 IS - 6 N2 - The primary endpoints in this study were the remission rates [final Hamilton Rating Scale for Anxiety (HAM-A) total score < or =7] and reduction from baseline in the HAM-A total score in patients with generalized anxiety disorder (GAD) and no associated depression. Patients with GAD (DSM-IV and HAM-A total score >18) were randomly assigned to treatment with venlafaxine XR or placebo for 8 weeks. A 1-week placebo run-in period preceded the double-blind phase. Patients with a >20% drop in their total HAM-A score during the run-in period, were excluded from the double-blind phase. All patients started therapy with 75 mg/day venlafaxine XR or matched placebo. Patients with less than 30% decrease in their HAM-A total score at the end of the second week, doubled their dose. Patients on the 150 mg/day dose underwent a 1-week taper period. Of the 24 patients in the venlafaxine XR group, 62.5% achieved remission versus 9.1% in the placebo group (P=0.0006). The mean decrease from baseline in HAM-A total score was 19.2 points for the venlafaxine XR group and 10.8 points for the placebo group (P<0.001). Eleven placebo-treated patients and seven venlafaxine XR treated patients doubled their dose at the end of the second week of double-blind treatment. No patient interrupted therapy because of side-effects. No changes in systolic or diastolic blood pressure were observed. Venlafaxine XR 75-150 mg/day was well tolerated. The remission rates achieved with venlafaxine 75-150 mg/day in non-depressed GAD patients were high with good tolerability. SN - 0268-1315 UR - https://www.unboundmedicine.com/medline/citation/15486518/Remission_rates_with_venlafaxine_extended_release_in_Greek_outpatients_with_generalized_anxiety_disorder__A_double_blind_randomized_placebo_controlled_study_ L2 - http://Insights.ovid.com/pubmed?pmid=15486518 DB - PRIME DP - Unbound Medicine ER -